Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,
UBS Group (NYSE:UBS) reported quarterly earnings of $0.55 per share. This is a 66.67 percent increase over earnings of $0.33 per share from the same period last year. The company reported $8.98 billion in sales this
Teva expects to use the net proceeds from the offerings, together with cash on hand, (i) to fund the announced tender offers to purchase, for cash, its 7.125% Senior Notes due 2025, 6.000% Senior